Life sciences executive search calibrating leadership to scientific stage, regulatory risk, and capital horizon — The credentials can be impeccable. The conditions can still be wrong.

Life Sciences Executive Search | Pharma, Biotech & MedTech

The science may be exceptional. The leadership conditions may not be.

Life sciences companies operate across unusually unforgiving boundaries. Scientific evidence must become regulatory approval. Regulatory approval must become a manufacturable product. Manufacturing must become reliable supply. And technical credibility must eventually become commercial performance.

Each transition requires a different kind of executive. The mistake is assuming that success at one stage automatically transfers to the next.

A research leader may not be calibrated to lead a clinical-stage company. A large-pharma executive may struggle inside a resource-constrained biotech. A quality leader from a mature multinational may not be a good fit for a rapidly scaling CDMO. A commercially accomplished operator may be the wrong fit for a company whose primary risk remains scientific.

The credentials can be impeccable. The conditions can still be wrong.

I advise boards, founders, investors, and leadership teams on retained life sciences executive search across pharmaceuticals, biotechnology, MedTech, CROs, CDMOs, and digital health, with particular depth across the U.S.–Mexico corridor and access to global life sciences markets through Alder Koten and IMD International Search Group.

→ Schedule a confidential consultation

The Leadership Model Is Changing

1. Science must cross the institutional threshold

Many life sciences companies reach the point where scientific conviction is no longer enough. The next leader must build governance, capital discipline, clinical execution, and organizational systems without weakening the science that created the company.

2. Manufacturing has become strategy

Supply resilience, quality, scale-up, technology transfer, and geographic diversification now sit at board level. Operations leaders are no longer managing production alone. They are protecting enterprise value.

3. The pipeline clock and the capital clock rarely agree

Clinical development, regulatory review, manufacturing readiness, and commercialization move on different timelines from investors and public markets. The executive must hold both clocks without allowing one to distort the other.

The CEO transitions across several of the world’s largest pharmaceutical companies in 2025 and 2026 reflect this broader reset. The next generation of leaders is being asked to integrate science, commerce, digital capabilities, regulation, and global operational complexity into a single role.

→ Read: Why Executives Fail: Conditions vs. Talent

Conditions-Based Life Sciences Executive Search

Most life sciences executive search processes begin with the resume. Mine begins with the conditions. Before approving the specification, the board must decide whether the primary risk is scientific, regulatory, operating, commercial, or organizational. Otherwise, the search will optimize the wrong profile.

Using the Race Conditions Model™, I diagnose six variables before defining the candidate profile.

1. Scientific stage

Discovery, preclinical, clinical development, regulatory submission, launch, or mature portfolio.

2. Capital environment

Founder-funded, venture-backed, private equity-owned, publicly traded, family-controlled, or part of a global multinational.

3. Primary value constraint

Science, enrollment, regulatory strategy, quality, manufacturing scale, supply continuity, market access, commercialization, or organizational maturity.

4. Operating model

Virtual biotech, integrated pharmaceutical company, medical-device manufacturer, CRO, CDMO, digital-health platform, or regional subsidiary.

5. Governance reality

Founder authority, board expectations, investor time horizon, decision rights, and the organization’s tolerance for risk.

6. Geographic complexity

Local market leadership, U.S.–Mexico manufacturing, Latin American commercialization, transatlantic regulation, or globally distributed operations. These conditions shape the search before the target-company list is built.

The question is not simply “who has done this job before?” It is “who has succeeded under conditions close enough to these, and what evidence suggests that success will transfer?”

→ Read: Driver Calibration Executive Assessment Framework

The Leadership Tensions I Assess

Life sciences executives rarely fail because they understand only one side of the role. They fail because they cannot hold both.

Scientific rigor ↔ commercial urgency
Quality discipline ↔ manufacturing throughput
Clinical patience ↔ investor time horizon
Founder conviction ↔ institutional governance
Global standards ↔ local execution
Innovation speed ↔ regulatory evidence
Portfolio focus ↔ business-development opportunity

The strongest candidate is not the person who chooses one side. It is the person who knows when each side must lead.

When a scientific founder becomes CEO, the judgment shifts from “what is true” to “what to do about it.” The first ninety days usually reveal whether the operating model can expand from scientific truth to institutional decision-making. When a corporate executive is installed into a scaling CDMO, the risk is different: the organization routes around the executive. The capability was real. The conditions did not allow it to transfer.

Life Sciences Sectors I Serve

I help companies with Life Sciences Executive Search in the following sectors:

Pharmaceuticals

Innovative pharma, specialty pharma, generics, biosimilars, and regional operating companies.

Biotechnology

Venture-backed and public biotech across oncology, immunology, rare disease, gene therapy, RNA therapeutics, and other advanced modalities.

Medical Devices & MedTech

Medical devices, diagnostics, fertility technology, digital therapeutics, surgical systems, and software-enabled medical products.

CROs & CDMOs

Clinical research, development, manufacturing, quality, technical operations, and supply-chain leadership.

Digital Health

Clinical data, AI-enabled diagnostics, patient platforms, health IT, and real-world evidence.

Animal Health

Veterinary pharmaceuticals, diagnostics, biotechnology, and production-animal health.

Life Sciences Executive Search Leadership Mandates

These are some of the examples of roles that I help with in Life Sciences Executive Search

Enterprise Leadership

CEO · President · Managing Director · COO · CFO · Chief Commercial Officer · CHRO

Scientific, Clinical & Medical

Chief Scientific Officer · Chief Medical Officer · VP Clinical Development · Head of Medical Affairs · Head of CMC

Regulatory, Quality & Compliance

VP Regulatory Affairs · VP Quality · Head of Compliance · Quality Systems Leadership · Regulatory Strategy

Manufacturing & Technical Operations

VP Manufacturing · Site Head · Plant Director · VP Technical Operations · MS&T · Engineering · Supply Chain

Commercial & Market Access

Commercial Leadership · Market Access · Pricing · Business Development · Licensing · Product Launch

Board & Advisory

Independent Directors · Scientific Directors · Audit and Compensation Committee Leaders · Scientific Advisory Board Members

I also support confidential CEO and functional succession. Life sciences companies frequently carry hidden dependency in scientific founders, regulatory leaders, quality executives, manufacturing heads, and key medical leaders. A departure can expose that the person was the system.

→ Read: Boutique vs. Large Executive Search Firms

U.S.–Mexico Life Sciences Executive Search – Leadership

Cross-border life sciences leadership requires more than language fluency. The executive must translate global quality, regulatory, and operating standards into a local system shaped by different labor dynamics, supplier markets, government relationships, infrastructure, and decision-making norms.

The most common mistake is assuming that formal authority transfers cleanly across borders. It does not.

A leader may understand FDA expectations but lack credibility on the manufacturing floor in Mexico. Another may understand the local operations but struggle to translate site-level realities into the language of a U.S. board or a global quality organization. Bilingual is useful. Bicultural calibration is the differentiator.

Under our Life Sciences Executive Search Practice, I assess whether the executive can operate across both systems without becoming a visitor to either.

→ Read: Executive Search 2026: U.S.-Mexico Cross-Border Trends

→ Read: Cross-Border Leadership: The Nearshoring Gap

Partner-Led Global Reach

I lead the conditions diagnosis, role definition, candidate assessment, and client advisory on the mandates I accept.

Where an assignment in the Life Sciences Executive Search realm requires local access outside my primary markets, I work with specialist partners through IMD International Search Group across major life sciences centers in North America, Europe, Latin America, and Asia-Pacific.

The model combines direct senior-consultant involvement with local market intelligence and cross-border access to candidates. Global reach is useful. Search ownership is what protects quality.

Choosing the Right Search Model

Large global firms can be the right choice for certain mandates. So can a partner-led firm. The decision should depend on the assignment, not the logo.

For life sciences executive search, I encourage clients to consider four key factors.

Off-limits exposure. Which target companies and candidate populations are unavailable to the firm you are considering?

Senior-consultant involvement. Who will diagnose the role, assess the candidates, and manage the client relationship?

Sector fluency. Can the adviser distinguish adjacent experience from genuinely transferable experience?

Search ownership. Will the same person who defines the conditions remain accountable through placement?

The search process matters. The judgment inside it matters more.

→ Read: Boutique vs. Large Executive Search Firms

Representative Life Sciences Executive Search Mandates

The following examples illustrate the types of leadership conditions these searches may involve.

The CDMO Quality-Throughput Bridge

A rapidly growing, PE-backed contract manufacturer needed a VP Quality who could maintain compliance under volume pressure without slowing production. The tension between quality and throughput is the defining leadership challenge for CDMOs, and candidates are often calibrated for only one side of that tension.

The Cross-Border Plant Leader

A multinational pharmaceutical company expanding manufacturing operations in central Mexico needed a Plant Director who could implement global GMP standards while navigating local regulatory relationships, labor dynamics, and supply logistics. The role demanded bicultural calibration, not just bilingual capability.

The Founder-to-CEO Transition

A Series B biotech with a platform technology needed to move from a founder-led scientific organization to an institutionally governed company capable of clinical-stage execution. The CEO search required someone who could earn the founder’s trust while building the organizational architecture the science alone couldn’t sustain.

The MedTech Quality–Innovation Bridge

An early-stage medical-device company needed a senior regulatory and quality leader who could build an FDA-ready quality system without importing the bureaucracy of a mature multinational. The mandate required hands-on experience across hardware, software, risk management, design controls, and supplier quality in a startup environment where the leader would build and govern.

Related Insights

Frequently Asked Questions

What makes life sciences executive search and assessment different?

Domain experience is necessary but insufficient. Candidates must be assessed against the company’s scientific stage, regulatory exposure, capital model, manufacturing complexity, and governance environment. Success in large pharma does not automatically transfer to biotech, CDMO, MedTech, or founder-led settings.

Which life sciences sectors do you serve?

Pharmaceuticals, biotechnology, medical devices and MedTech, CROs and CDMOs, digital health, and animal health, from venture-backed startups to public companies and multinational subsidiaries.

Do you recruit regulatory and quality leaders for MedTech?

Yes. MedTech regulatory and quality mandates typically require experience across FDA pathways, ISO 13485, design controls, software and hardware risk management, supplier quality, quality management systems, and regulatory submissions. The assessment focuses on whether the leader can build systems appropriate to the company’s stage rather than import processes built for a different scale.

Do you recruit life sciences leaders in Mexico?

Yes. The practice has particular depth in U.S.–Mexico manufacturing and regional leadership: plant directors, quality and regulatory executives, and general managers who can translate global standards into local operating reality.

Can you support confidential CEO succession?

Yes. Life sciences succession often involves founder transitions, incumbent replacement, board alignment, and hidden dependencies on individual leaders. Search strategy, outreach, and communications can be structured to protect confidentiality throughout.

How long does a retained life sciences executive search take?

The initial qualified slate is commonly developed within several weeks. Total time to appointment depends on role complexity, scientific specialization, location, confidentiality, assessment stages, notice periods, and board availability.

Before You Define the Role

A clinical-stage biotech does not need the same CEO as a commercial-stage platform. A CDMO under quality pressure does not need the same operations leader as one preparing for rapid expansion.

A MedTech company building its first quality system does not need the same executive as a mature manufacturer preparing for remediation.

The title may be identical. The conditions are not.

If you are planning a life sciences leadership appointment, succession, manufacturing expansion, or confidential replacement, the first conversation should determine what the organization actually requires before approaching the market.

Charlie Solórzano, Managing Partner, Alder Koten IMD International Search Group — Life Sciences Executive Search Practice

📞 +1 (713) 337-7943 📧 carlos.solorzano@alderkoten.com

Houston, Texas — 9595 Six Pines Drive, Suite 8210, The Woodlands, TX 77382

Zapopan, Jalisco — Paseo Andares, Puerta de Hierro, 45116 Zapopan, Jalisco, Mexico

The molecule may be the same. The leadership conditions never are.

Charlie Solórzano is a Managing Partner at Alder Koten, a boutique executive search firm specializing in C-suite and board placements across the U.S. and Mexico markets. He advises founders, investors, and boards on leadership transitions using The Race Conditions Model™, a proprietary diagnostic framework built on the thesis that leadership success is determined by conditions, not credentials.

Before You Define the Role

A clinical-stage biotech does not need the same CEO as a commercial-stage platform. If you are planning a life sciences leadership appointment, succession, or confidential replacement, the first conversation should determine what the organization actually requires before the market is approached.

Schedule a Confidential Consultation